The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results